Accenture consultants Jeff Elton and Anne O’Riordan argue that coming changes in health care should benefit patients and humanity at large. They assert that drug companies and device makers will come to pursue business models that profit from curing people, not from pushing pills. Their enthusiasm is enviable, although their writing style can be turgid. If you’re not already versed in health care, you also may have a hard time with their insider argot. And Trump administration changes in Obamacare could outdate some of their overview. While always politically neutral, getAbstract suggests this thought-provoking study to health professionals, patients and investors.
About the Authors
Jeff Elton, managing director of Accenture Strategy, has founded several health care companies. Anne O’Riordan is global industry senior managing director of Accenture Life Sciences.
Comment on this summary
In our Journal
2 years ago
Digital Technologies Come of Age in Health Care
From gene therapy to AI-driven diagnosis to 3D printed tissue – the future of medicine has arrived. The health care industry continues to grow at breakneck speed fueled by the great promise of emerging biomedical and AI-driven technologies, as well as the need to update legacy systems. Silicon Valley tech companies are wading into the […]